Relievant Medsystems is a technology company.
Relievant Medsystems has raised $219.0M across 6 funding rounds.
Relievant Medsystems has raised $219.0M in total across 6 funding rounds.
Relievant Medsystems has raised $219.0M in total across 6 funding rounds.
Relievant Medsystems's investors include Canaan Partners, Lightstone Ventures, Morgenthaler Ventures, Questa Capital, Vensana Capital.
Relievant Medsystems is a privately held medical device company founded in 2006 that developed the Intracept® System, a minimally invasive procedure targeting the basivertebral nerve to provide lasting relief for patients with chronic vertebrogenic low back pain (CLBP) originating from degenerative disc disease with Modic changes.[1][2][3] The company serves spine surgeons, orthopedic surgeons, neurological surgeons, and interventional pain physicians, addressing a significant unmet need for millions suffering from CLBP where traditional treatments like surgery or opioids fall short.[1][3] With estimated annual revenue of $78.8M, 251 employees, and $271M in total funding, Relievant demonstrated strong growth before its acquisition by Boston Scientific in November 2023 for an upfront $850M plus contingent payments.[1][4]
The Intracept procedure delivers targeted energy to block pain signal transmission in the spine, backed by clinical trials showing long-term durability, and gained expanded U.S. coverage from major payers like Anthem, Humana, and Cigna, reaching over 150 million lives.[3][4]
Relievant Medsystems was founded in 2006 in Minneapolis, MN, with additional offices in Sunnyvale, CA, focusing on innovative solutions for chronic low back pain.[1][2] Key leaders include President & CEO Tyler Binney and Chief Medical Officer Ray Baker, who drove the development of the Intracept System amid growing recognition of vertebrogenic pain as a distinct CLBP subtype identifiable by Modic changes on MRI.[1][3]
The idea emerged from the need for targeted, minimally invasive therapies beyond conservative care or fusion surgery; early traction came from FDA clearance as the only device for vertebrogenic pain treatment, clinical validations, and $58M in venture funding in 2018, building toward commercial scale and payer adoption.[1][4]
Relievant rides the wave of precision pain management in medtech, targeting vertebrogenic pain—a biomarker-driven subset of the $100B+ CLBP market—amid rising demand for non-opioid, evidence-based alternatives post-opioid crisis.[1][3][4] Timing aligns with FDA clearances, payer policies favoring procedures with proven outcomes, and medtech consolidation, as seen in Boston Scientific's acquisition to bolster its neuromodulation portfolio with multi-target pain solutions.[4][5]
Market forces like aging populations, diagnostic advances (e.g., Modic changes), and coverage for 150M+ lives amplify its influence, shifting ecosystems toward basivertebral nerve interventions and integrating into larger platforms for global reach.[4]
Post-acquisition by Boston Scientific in 2023, Relievant’s Intracept technology integrates into a leading medtech giant’s chronic pain offerings, with expected accretion to earnings by 2025 and sales-contingent milestones driving expansion.[4] Trends like payer expansions, further clinical data, and AI-enhanced diagnostics will accelerate adoption, potentially evolving its influence from niche innovator to standard-of-care in vertebrogenic pain therapies worldwide.[3][4][5] This positions Relievant to transform millions more lives, reinforcing its origins in targeted spine solutions.
Relievant Medsystems has raised $219.0M across 6 funding rounds. Most recently, it raised $70.0M Series F in October 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2020 | $70.0M Series F | Canaan Partners, Lightstone Ventures, Morgenthaler Ventures, Questa Capital, Vensana Capital | |
| Jun 1, 2018 | $58.0M Series E | Canaan Partners | |
| Oct 1, 2016 | $36.0M Series D | Canaan Partners, Lightstone Ventures, Morgenthaler Ventures | |
| Mar 1, 2012 | $30.0M Series D | Canaan Partners, Lightstone Ventures, Morgenthaler Ventures | |
| Jul 1, 2009 | $20.0M Series C | Canaan Partners, Lightstone Ventures, Morgenthaler Ventures | |
| Oct 1, 2006 | $5.0M Series B | Canaan Partners |